

# Philipp Le Coutre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10716843/publications.pdf>

Version: 2024-02-01

57  
papers

6,895  
citations

172457

29  
h-index

149698

56  
g-index

57  
all docs

57  
docs citations

57  
times ranked

5197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	7.2	43
2	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	7.2	159
3	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	1.4	147
4	CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 736137.	4.8	2
5	Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 772809.	2.8	4
6	Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. <i>Acta Haematologica</i> , 2020, 143, 217-231.	1.4	26
7	Single-cell analysis based dissection of clonality in myelofibrosis. <i>Nature Communications</i> , 2020, 11, 73.	12.8	46
8	The role of bosutinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 4395-4408.	2.4	26
9	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	1.4	13
10	Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment. <i>Ecancermedalscience</i> , 2020, 14, 1089.	1.1	6
11	HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells. <i>Scientific Reports</i> , 2019, 9, 14029.	3.3	3
12	Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 555-567.	2.1	4
13	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1589-1599.	2.5	21
14	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	27.0	257
15	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-237.	1.6	356
16	Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. <i>Blood</i> , 2018, 132, 460-460.	1.4	6
17	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	1.4	8
18	Nilotinib. <i>Recent Results in Cancer Research</i> , 2018, 212, 69-85.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1225-1233.	2.5	9
20	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , 2017, 96, 1303-1313.	1.8	16
21	Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2017, 98, 160-168.	2.2	9
22	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	10.7	214
23	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	4.1	47
24	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. <i>Blood</i> , 2015, 125, 901-906.	1.4	239
25	Article Commentary: Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer. <i>Biomarker Insights</i> , 2015, 10s3, BMI.S22432.	2.5	3
26	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	4.1	181
27	Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. <i>European Journal of Haematology</i> , 2015, 95, 498-506.	2.2	29
28	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. <i>Blood</i> , 2015, 126, 2775-2775.	1.4	3
29	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , 2014, 123, 2317-2324.	1.4	167
30	Nilotinib. <i>Recent Results in Cancer Research</i> , 2014, 201, 67-80.	1.8	14
31	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014, 124, 3135-3135.	1.4	43
32	Clinical cardiac safety profile of nilotinib. <i>Haematologica</i> , 2012, 97, 883-889.	3.5	92
33	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 345-350.	2.3	25
34	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2351-2361.	1.3	90
35	Expanding Nilotinib Access in Clinical Trials (ENACT). <i>Cancer</i> , 2012, 118, 118-126.	4.1	61
36	Omacetaxine mepesuccinate for the treatment of leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2381-2392.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Severe Peripheral Arterial Disease During Nilotinib Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1347-1348.	6.3	145
38	The expanding role of nilotinib in chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 97-107.	2.4	3
39	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	6.3	362
40	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2251-2259.	27.0	1,497
41	Activity and tolerability of nilotinib. <i>Cancer</i> , 2010, 116, 4564-4572.	4.1	20
42	New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 1771-1780.	7.0	23
43	Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Thyroid</i> , 2010, 20, 1209-1214.	4.5	61
44	Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. <i>Haematologica</i> , 2010, 95, 582-588.	3.5	41
45	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. <i>Expert Review of Hematology</i> , 2010, 3, 665-673.	2.2	39
46	Nilotinib. <i>Recent Results in Cancer Research</i> , 2010, 184, 103-117.	1.8	4
47	Nilotinib for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2008, 1, 29-39.	2.2	6
48	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	1.4	284
49	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. <i>Blood</i> , 2007, 110, 3540-3546.	1.4	688
50	Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 34, 181-185.	1.4	67
51	Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 313-323.	2.3	137
52	Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome. <i>American Journal of Hematology</i> , 2003, 73, 249-255.	4.1	12
53	Determination of Î±-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 28, 75-85.	1.4	52
54	Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. <i>Blood</i> , 2000, 95, 1758-1766.	1.4	454

#	ARTICLE	IF	CITATIONS
55	In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. Journal of the National Cancer Institute, 1999, 91, 163-168.	6.3	341
56	Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis. Blood Cells, Molecules, and Diseases, 1997, 23, 380-394.	1.4	273
57	Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls. EJHaem, 0, , .	1.0	0